Certara (Certara) Cash, Cash Equivalents, Marketable Securities : $224.8 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Certara Cash, Cash Equivalents, Marketable Securities?

Certara's quarterly cash, cash equivalents, marketable securities declined from Sep. 2023 ($272.31 Mil) to Dec. 2023 ($234.95 Mil) but then stayed the same from Dec. 2023 ($234.95 Mil) to Mar. 2024 ($224.78 Mil).

Certara's annual cash, cash equivalents, marketable securities increased from Dec. 2021 ($185.80 Mil) to Dec. 2022 ($236.59 Mil) but then declined from Dec. 2022 ($236.59 Mil) to Dec. 2023 ($234.95 Mil).

Certara Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Certara's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Certara Cash, Cash Equivalents, Marketable Securities Chart

Certara Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

29.26

271.38

185.80

236.59

234.95

Certara Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															244.14	245.19	272.31	234.95	224.78

Certara Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Certara (NAS:CERT) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Certara Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Certara's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Certara (Certara) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Certara Inc (NAS:CERT) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Overlook Center, Suite 101, Princeton, NJ, USA, 08540

Website

https://www.certara.com

Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The group has a business presence in the United States, EMEA, and other regions, of which a majority of revenue is derived from the United States.

Executives

Richard M. Traynor	officer: See Remarks	1114 AVENUE OF THE AMERICAS, 45TH FLOOR, NEW YORK NY 10036
Leif E Pedersen	officer: President, Software	10188 TELESIS COURT, SUITE 100, SAN DIEGO CA 92121
Eran Broshy	director	C/O VENTIV HEALTH, 200 COTTONTAIL LN. VANTAGE COURT N., SOMERSET NJ 08873
Patrick F Smith	officer: PRESIDENT, INTEGRATED DRUG DEV	C/O CERTARA, INC., 100 OVERLOOK CENTER, SUITE 101, PRINCETON NJ 08540
John E Gallagher	officer: CHIEF FINANCIAL OFFICER	BECTON, DICKINSON AND COMPANY, FRANKLIN LAKES NJ 07417
Arsenal Saturn Holdings Lp	10 percent owner	C/O ARSENAL CAPITAL PARTNERS, 100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
Jeffrey B. Kovach	10 percent owner	C/O ARSENAL CAPITAL PARTNERS, 100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
Arsenal Capital Partners Iii-b Lp	10 percent owner	100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
Terrence M. Mullen	10 percent owner	C/O ARSENAL CAPITAL PARTNERS, 100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
Eqt Avatar Parent L.p.	10 percent owner	100 OVERLOOK CENTER, SUITE 101, PRINCETON NJ 08540
Arsenal Capital Investment Iii Lp	10 percent owner	C/O ARSENAL CAPITAL PARTNERS, 100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
Arsenal Capital Investment Vi Lp	10 percent owner	C/O ARSENAL CAPITAL PARTNERS, 100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
Arsenal Capital Partners Iii Lp	10 percent owner	100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
David Spaight	director	100 OVERLOOK CENTER, SUITE 101, PRINCETON NJ 08540
Mason P Slaine	director	2777 SUMMER STREET, SUITE 209, STAMFORD CT 06905